TPF INDUCTION CHEMOTHERAPY AND ABT-888 (VELIPARIB) - A PHASE 1/RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Trial Profile

TPF INDUCTION CHEMOTHERAPY AND ABT-888 (VELIPARIB) - A PHASE 1/RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Veliparib (Primary) ; Cisplatin; Docetaxel; Fluorouracil; Hydroxycarbamide; Paclitaxel
  • Indications Head and neck cancer; Human papillomavirus infections; Hypopharyngeal cancer; Laryngeal cancer; Nasopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer; Salivary gland cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Mar 2017 Status changed from suspended to recruiting.
    • 16 Jan 2017 Status changed from recruiting to suspended for assessment. Contact ctsucontact@westat.com for specifics.
    • 12 Sep 2016 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top